ClinicalTrials.gg
CompletedNCT03073148Updated Nov 17, 2020Results posted

Evaluation of Tangible Boost Replenishing System

An interventional study of Tangible Boost and Placebo saline in Contact Lens Solution, sponsored by Tangible Science. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-17.

Sponsored by Tangible Science · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate Tangible Boost, a new contact lens care product which is designed to replenish the hydrogel layer on fluorosilicone acrylate lenses with Hydra-PEG. The Hydra-PEG coating is a poly(ethylene glycol)-based hydrogel that is covalently bound to the lens surface. This coating improves lens wettability, a common cause of patient discomfort. Tangible Boost is designed to maintain the wettability of Hydra-PEG lenses throughout the lens lifetime. Patients can use the Tangible Boost kit to reapply the Hydra-PEG coating each month at home.

02

Conditions studied

  • Contact Lens Solution

Keywords

  • Contact Lens Care Accessory
03

In context

Lead sponsor

Tangible Science is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Habitual contact lens wear with a group 3 FDA approved rigid lens material, with 20-50% of subjects wearing corneal lenses
  • Willing and able to sign the form
  • 18 years or older

Exclusion criteria

Exclusion Criteria:

  • Eye injury or surgery within the 3 months immediately prior to enrollment for this trial
  • Pre-existing ocular irritation that would preclude contact lens fitting
  • Current enrollment in an ophthalmic clinical trial
  • Evidence of systemic or ocular abnormality, infection, or disease which is likely to affect successful wear of contact lenses or use of the accessory solutions, as determined by the investigator
  • Any use of medications for which contact lens wear could be , as determined by the investigator
  • Pregnant women and nursing mothers
  • Visual acuity less than 20/20 when best corrected with contact lenses
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Tangible Boost

    Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.

    Device: Tangible Boost

  • Placebo comparator
    Control

    Participants will treat their lenses with a placebo "Tangible Boost" kit containing saline after 30 days and again after 60 days.

    Other: Placebo saline

Interventions

  • DeviceTangible Boost

    Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.

  • OtherPlacebo saline

    Participants will treat their lenses with a placebo "Tangible Boost" kit, which contains saline in place of the Tangible Boost solution.

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Event Reports or Discontinuations

    A report of any adverse events or discontinuations that may have occurred. This measure includes adverse events unrelated to the treatment. See adverse events section for additional details.

    Time frame: Duration of study, 90 +/- 7 days after lens dispense visit.

  2. Corneal Staining

    Corneal staining with lissamine green was used to identify damage to the corneal cells, which may have been caused by the contact lenses or treatments in the study. 5 regions in each eye were scored on a scale of 0-4, resulting in a total possible range of 0-20. Left and right eye scores were averaged for each subject. A lower score indicates less corneal damage.

    Time frame: 1 day after treatment (day 31), final assessment (day 90)

  3. Visual Acuity

    Visual acuity was calculated on a logMAR scale using high luminance, high contrast acuity charts. On the logMAR scale, a score of 0 indicates no vision loss, with higher scores indicating more vision loss.

    Time frame: 1 day after treatment (day 31), final assessment (day 90)

  4. Non-invasive Tear Film Break-up Time

    Tear break-up time was measured with the OCULUS Keratograph.

    Time frame: 1 day after treatment (day 31), final assessment (day 90)

  5. Number of Participants With Acceptable Lens Fit

    Count of participants with acceptable lens fit (movement, centration, apical clearance, limbal clearance, and landing zone).

    Time frame: final assessment (day 90)

Secondary outcomes

  1. CLDEQ Score

    The Contact Lens Dry Eye Questionnaire (CLDEQ) is used to evaluate the dry eye symptomology of contact lens wearers on a scale of 0-39. A lower score is indicative of greater comfort.

    Time frame: 1 day after treatment (day 31), final assessment (day 90)

  2. Visual Analog Scale (VAS)

    The subjective comfort of lenses was evaluated on a scale of 0-100, with higher scores indicating better comfort.

    Time frame: 1 day after treatment (day 31), final assessment (day 90)

07

Results

Posted Nov 17, 2020
Limitations and caveats
Decline in performance of the Hydra-PEG lenses was not observed in the control group; therefore, there was little opportunity to see improvements in outcome measures in the treatment group.

Participant flow

Participant flow — Overall Study
MilestoneTangible BoostControlUnassigned
Started21104
Completed21100
Not completed004

Outcome measures

PrimaryNumber of Patients With Adverse Event Reports or Discontinuations

A report of any adverse events or discontinuations that may have occurred. This measure includes adverse events unrelated to the treatment. See adverse events section for additional details.

Time frame:
Duration of study, 90 +/- 7 days after lens dispense visit.
Reported as:
Count of participants · Participants
Number of Patients With Adverse Event Reports or Discontinuations
ParticipantsTangible BoostControlUnassigned
Number of Patients With Adverse Event Reports or Discontinuations424
PrimaryCorneal Staining

Corneal staining with lissamine green was used to identify damage to the corneal cells, which may have been caused by the contact lenses or treatments in the study. 5 regions in each eye were scored on a scale of 0-4, resulting in a total possible range of 0-20. Left and right eye scores were averaged for each subject. A lower score indicates less corneal damage.

Time frame:
1 day after treatment (day 31), final assessment (day 90)
Reported as:
Median · score on a scale
Corneal Staining
score on a scaleTangible BoostControl
1 day after treatment2.25 (.5 to 5.125)2.00 (.75 to 4.50)
Final assessment1.5 (0 to 3.25)1.75 (0.75 to 4.375)
Statistical analysis
  • Tangible Boost · ANOVA · p = 0.3577Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.
  • Control · ANOVA · p = 0.9917Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.
PrimaryVisual Acuity

Visual acuity was calculated on a logMAR scale using high luminance, high contrast acuity charts. On the logMAR scale, a score of 0 indicates no vision loss, with higher scores indicating more vision loss.

Time frame:
1 day after treatment (day 31), final assessment (day 90)
Reported as:
Median · logMAR visual acuity
Visual Acuity
logMAR visual acuityTangible BoostControl
1 day after treatment0.12 (-.025 to 0.165)0.095 (-0.07 to 0.225)
final assessment0.140 (0.020 to 0.225)0.060 (-0.0225 to 0.2725)
Statistical analysis
  • Tangible Boost · ANOVA · p = 0.3239Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.
  • Control · ANOVA · p = 0.8343Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.
PrimaryNon-invasive Tear Film Break-up Time

Tear break-up time was measured with the OCULUS Keratograph.

Time frame:
1 day after treatment (day 31), final assessment (day 90)
Reported as:
Mean · seconds
Non-invasive Tear Film Break-up Time
secondsTangible BoostControl
1 day after treatment16.27 ± 4.3219.84 ± 6.37
final assessment15.84 ± 4.6418.30 ± 3.49
Statistical analysis
  • Tangible Boost · ANOVA · p = 0.4134Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.
  • Control · ANOVA · p = 0.1192Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.
PrimaryNumber of Participants With Acceptable Lens Fit

Count of participants with acceptable lens fit (movement, centration, apical clearance, limbal clearance, and landing zone).

Time frame:
final assessment (day 90)
Reported as:
Count of participants · Participants
Number of Participants With Acceptable Lens Fit
ParticipantsTangible BoostControl
Number of Participants With Acceptable Lens Fit2110
SecondaryCLDEQ Score

The Contact Lens Dry Eye Questionnaire (CLDEQ) is used to evaluate the dry eye symptomology of contact lens wearers on a scale of 0-39. A lower score is indicative of greater comfort.

Time frame:
1 day after treatment (day 31), final assessment (day 90)
Reported as:
Mean · score on a scale
CLDEQ Score
score on a scaleTangible BoostControl
1 day after treatment14.2 ± 8.97.9 ± 7.7
final assessment16.7 ± 8.011.4 ± 9.5
Statistical analysis
  • Tangible Boost · ANOVA · p = 0.1753 (Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.)Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.
  • Control · ANOVA · p = 0.1843Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.
SecondaryVisual Analog Scale (VAS)

The subjective comfort of lenses was evaluated on a scale of 0-100, with higher scores indicating better comfort.

Time frame:
1 day after treatment (day 31), final assessment (day 90)
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS)
score on a scaleTangible BoostControl
1 day after treatment78 ± 2393 ± 9
final assessment75 ± 2284 ± 20
Statistical analysis
  • Tangible Boost · ANOVA · p = 0.0765Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.
  • Control · ANOVA · p = 0.1520Repeated measures ANOVA comparing baseline, 1 day after treatment, and final assessment.

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tangible Boost0/21 (0%)0/21 (0%)4/21 (19%)
Control0/10 (0%)0/10 (0%)2/10 (20%)
Unassigned0/4 (0%)0/4 (0%)1/4 (25%)
Most frequent other events
Most frequent other events
EventTangible BoostControlUnassigned
Corneal HydropsEye disorders0/210/101/4
Acute inflammatory conjunctivitisEye disorders0/211/100/4
Mild conjunctival inflammationEye disorders0/211/100/4
Respiratory InfectionRespiratory, thoracic and mediastinal disorders1/210/100/4
Asymptomatic keratitisEye disorders1/210/100/4
Mild, allergic-type reactionEye disorders1/210/100/4
Preservative toxicity-type corneal sensitivityEye disorders1/210/100/4
Contact lens associated red eyeEye disorders1/210/100/4

Baseline characteristics

Baseline measures are provided for all participants who were assigned to a study arm. Participants who dropped out of the study prior to assignment are not included.

Age, Continuous
Age, Continuous(years)Tangible BoostControlTotal
Mean47 ± 1646 ± 1647 ± 15
Sex: Female, Male
Sex: Female, Male(Participants)Tangible BoostControlTotal
Female15419
Male6612
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Tangible BoostControlTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Tangible BoostControlTotal
United States211031
Corneal Staining
Corneal Staining(units on a scale)Tangible BoostControlTotal
Median2.0 (0.25 to 3.75)2.0 (0 to 5.63)2.0 (0 to 4.5)
Visual Acuity (logMAR)
Visual Acuity (logMAR)(units on a scale)Tangible BoostControlTotal
Median0.11 (0.01 to 0.20)0.11 (-0.02 to 0.23)0.11 (0 to 0.20)
Non-invasive tear film break-up time
Non-invasive tear film break-up time(seconds)Tangible BoostControlTotal
Mean17.40 ± 4.8114.91 ± 6.4816.59 ± 5.60
Lens Fit
Lens Fit(Participants)Tangible BoostControlTotal
Count of participants211031

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Houston
    Houston, Texas 77204, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Feb 2019, 23 months.

Results were first posted in Nov 2020, 1 year 9 months after primary completion. A results delay was requested in Jan 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2017
First posted
Mar 8, 2017
StartActual
Feb 24, 2017
Primary completionActual
Feb 13, 2019
CompletionActual
Feb 13, 2019
Results delay requested
Jan 31, 2020
Results first posted
Nov 17, 2020
Last update
Nov 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03073148
Lead sponsor
Tangible Science
Responsible party
Sponsor
First posted
Mar 8, 2017
Start date
Feb 24, 2017
Primary completion
Feb 13, 2019
Completion
Feb 13, 2019
Results posted
Nov 17, 2020
Last update
Nov 17, 2020

Study contacts

Maria K Walker, OD MS
principal investigator · University of Houston

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion